Revue d''Homeopathie最新文献

Le médicament homéopathique Cedrus libani, lors d’une expérimentation pathogénétique multicentrique réalisée en 2016, a présenté des propriétés thérapeutiques inattendues, sur la sphère cardiovasculaire en traitement de congestions touchant la partie supérieure du corps, chez des patients au profil psychologique particulier. La forte charge symbolique liée à cet arbre très impliqué dans les trois religions monothéistes s’est exprimée dans les témoignages des expérimentateurs et dans les tableaux cliniques des premiers cas guéris. Une étude de la botanique et des mythes liés à cet arbre permet d’appréhender la richesse de ce médicament, avant que d’autres expériences cliniques viennent en confirmer les indications.

The homeopathic medicinal product Cedrus libani featured unexpected therapeutic properties during a multicentre pathogenetic trial performed in 2016, concerning the treatment of vascular congestion in the upper part of the body for patients with a specific psychological profile. The important symbolism linked to this tree, involved in the three main monotheistic religions expressed itself in the experimenters’ testimonies and in the clinical pictures of the few cured cases. The study of the botany and of the myths regarding the tree gives us an insight into the richness of this medicine, before further clinical practices confirm its indications.

Les inhibiteurs de poly-ADP-ribose-polymérase (iPARP) sont une nouvelle classe de thérapie ciblée qui bloquent les mécanismes de réparation de l’ADN des cellules cancéreuses provoquant leur apoptose. Ils sont essentiellement utilisés dans les cancers de l’ovaire en prévention des récidives. Les effets secondaires les plus fréquents sont les nausées et la fatigue ; les plus graves sont les toxicités sanguines.

Prescrits sur plusieurs mois, des soins de support de qualité sont indispensables pour améliorer la qualité de vie et par voie de conséquence, l’observance des iPARP. Dans notre expérience, l’utilisation de l’homéopathie et d’ultra-hautes dilutions d’iPARP dynamisées permet une diminution des effets secondaires et représente une aide précieuse pour les malades. L’absence d’interactions médicamenteuses autorise leur utilisation en toute sécurité. Le faible coût et la très bonne tolérance de ce traitement de support favorise son acceptabilité par les patientes. Des études cliniques préliminaires devraient être initiées pour confirmer notre impression clinique favorable.

Poly-ADP-ribose-polymerase inhibitors (iPARP) are a new class of targeted therapy which block the DNA repair mechanisms of cancer cells causing their apoptosis. They are mainly used in ovarian cancers to prevent a recurrence. The most common side effects are nausea and fatigue; the most serious are blood toxicities.

Prescribed over several months, supportive care is essential to improve quality of life and consequently compliance with iPARPs. In our experience, the use of homeopathy and of ultra-high dilutions of iPARP reduces side effects and is a great help to patients. The lack of drug interactions makes it possible for them to be used safely. The low cost and very good tolerance of this supportive treatment make it very acceptable to patients. Preliminary clinical studies should be carried out to confirm our favourable clinical impression.

Introduction

Since the 1 ^st January 2021, homeopathy is no longer paid for by the French National Insurance system. Without drug interference and significant side effects, popular with two-thirds of French people, homeopathy is by far the most used complementary medicine, whatever the disease. What is its real merit and what are the risks for patients with chronic conditions of having to pay for the actual cost of their medicine without any help from the French National insurance system?

Method

Review of the literature concerning the use of homeopathy in cancer care support.

Results

Homeopathy is the most widely used complementary medicine in oncology (30.7% of patients) with a very high percentage of satisfaction. The improvement in the quality of life has been shown in several studies. Better compliance with conventional cancer treatments has also made it possible to demonstrate an improvement in survival rates. Prescribed in 75% of cases by doctors, the use of homeopathy does not lead to refusal of treatment and is more and more often accepted or even recommended by oncologists. The latter are informed of these treatments in 83% of cases.

Discussion

The average prescription, respecting the recommendations of the International Homeopathic Society for Supportive Care in Oncology, is around € 50 per month. This can represent a medico-social handicap in long-term illnesses. Stopping or reducing homeopathy for economic reasons not only endangers the quality of life of these patients but also puts at risk their observance of conventional treatments with its consequent loss of opportunity.

Conclusion

We believe it is essential and urgent for the French national insurance system to return to paying for homeopathy in the framework of supportive care for long-term illnesses.

Context

In the early 20 th century, Antoine Nebel developed a new chronic reactive mode (CRM), tuberculinism, in addition to the three “miasms” already described by Hahnemann: psora, sycosis and syphilis. How does tuberculinism fit in within the three other CRMs today?

Goal

To provide diagnostic elements so as to identify the tuberculinic CRM of a patient. To suggest the most effective therapeutic strategy.

Method

By comparing the writings of twentieth century authors with our clinical experience, we will offer the essential features and pathognomonic of tuberculinism as well as its treatment.

Results

Tuberculinism is an inherited or acquired CRM, very common in children and adolescents. It often occurs when there is a family history of tuberculosis or following BCG vaccination or repeated antibiotic therapy for recurrent ENT disorders. It evolves in two stages, acceleration of cellular metabolism then progressive exhaustion. Individuals with a phosphoric constitution are more affected. Morbid manifestations mainly evoke psora but also sycosis.

Conclusion

The recognition and management of the tuberculinic CRM make it possible to effectively treat recurrent and chronic respiratory diseases, which are very debilitating for children as well as for their parents.

Context

In the early 20 ^th century Antoine Nebel developed a new chronic reactive mode (CRM), tuberculinism, in addition to the three diatheses already described by Samuel Hahnemann: psora, sycosis and syphilis. Today, what is the exact place of tuberculinism within the three other CRM?

Goal

To provide the diagnostic elements to identify the tuberculinic MRC of a patient. To locate this CRM among the 3 previous ones. To suggest the most effective therapeutic strategy.

Method

By comparing the writings of the authors of the twentieth century with our clinical experience, we will identify the essential characteristics and the pathognomonic tuberculinism as well as its treatment.

Results

Tuberculinism is an inherited or acquired CRM, very common in children and adolescents. It often occurs when there is a family history of tuberculosis or following BCG vaccination or repeated antibiotic therapy for recurrent ENT disorders. It evolves in two stages, acceleration of cell metabolism then progressive exhaustion. Individuals with a phosphoric constitution are more affected. Morbid manifestations mainly evoke psora but also sycosis.

Conclusion

The recognition and management of the tuberculinic CRM make it possible to effectively treat recurrent and chronic respiratory diseases, which are very debilitating for children as well as for their parents.

Introduction

Depuis le 1^er janvier 2021, l’homéopathie n’est plus remboursée en France. Dépourvue d’interférence médicamenteuse et d’effets secondaires notables, plébiscitée par les deux-tiers des Français, l’homéopathie est de loin la médecine complémentaire la plus utilisée, toutes pathologies confondues. Quel est son intérêt réel et quels sont les risques que représente son déremboursement pour les patients atteints de pathologies chroniques ?

Méthode

Revue de la littérature concernant l’utilisation de l’homéopathie en soins oncologiques de support.

Résultats

L’homéopathie est la médecine complémentaire la plus utilisée en cancérologie (30,7 % des patients) avec un pourcentage de satisfaction très élevé. L’amélioration de la qualité de vie a été montrée par plusieurs études. La meilleure observance des traitements conventionnels du cancer a également permis de mettre en évidence une amélioration de la survie. Prescrite dans 75 % des cas par des médecins, l’utilisation de l’homéopathie n’entraîne pas de refus des traitements et se trouve de plus en plus souvent acceptée, voire conseillée par les oncologues. Ceux-ci sont tenus informés de ces traitements dans 83 % des cas.

Discussion

L’ordonnance moyenne, respectant les recommandations de la Société Homéopathique Internationale de Soins de Support en Oncologie est d’environ 50€ par mois. Cela peut représenter un handicap médico-social dans les affections de longue durée. L’arrêt ou la diminution de l’homéopathie pour des raisons économiques risque de mettre en péril la qualité de vie de ces patients mais aussi l’observance des traitements conventionnels avec comme corollaire une perte de chance.

Conclusion

Il nous paraît indispensable et urgent de rétablir le remboursement de l’homéopathie dans le cadre des soins de support des affections de longue durée.

Introduction

Since the 1st January 2021, homeopathy is no longer paid for by the French National Insurance system. Without drug interference and significant side effects, popular with two-thirds of French people, homeopathy is by far the most used complementary medicine, whatever the disease. What is its real merit and what are the risks for patients with chronic conditions of having to pay for the actual cost of their medicine without any help from the French National insurance system?

Method

Review of the literature concerning the use of homeopathy in cancer care support.

Results

Homeopathy is the most widely used complementary medicine in oncology (30.7% of patients) with a very high percentage of satisfaction. The improvement in the quality of life has been shown in several studies. Better compliance with conventional cancer treatments has also made it possible to demonstrate an improvement in survival rates. Prescribed in 75% of cases by doc